1Wada T, Yasunaga H, lnokuchi R, et al. Effects of edaravone on early outcomes in acute ischemic stroke patients treated with recombinant tissue plasminogen activator[J]. J Neurol Sci, 2014, 345:106-111.
2Lasek-Bal A, Puz P, Kazibutowska Z. Efficacy and safety assessment of alteplase in the treatment of stroke-gender differences[J]. Neurol Res, 2014, 36:851-856.
3Cuzick J, Thorat MA, Bosetti C, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population[J]. Ann Oncol, 2015, 26:47-57.
4Hennekens CH, Dalen JE. Aspirin in the treatment and prevention of cardiovascular disease:past and current perspectives and future directions[J]. AM J Med, 2013, 126:373-378.
5Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease[J]. AM J Med, 2011,124:621-629.
6Dai Y, Ge J. Clinical use of aspirin in treatment and prevention of cardiovascular disease[J]. Thrombosis, 2012:2012245037.
7Connolty BJ, Pearce LA, Kurth T, et al. Aspirin therapy and risk of subdural hematoma:meta-analysis of randomized clinical trials[J]. J Stroke Cerebrovasc Dis, 2013, 22:444-448.
8Rist PM, Buring JE, Kase CS, et al. Effect of low-dose aspirin on functional outcome from cerebral vascular events in women[J]. Stroke, 2013, 44:432-436.
9Xie M, Shan Z, Zhang Y, et al. Aspirin for primary prevention of cardiovascular events:meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status[J]. PLoS one, 2014, 9:e90286.
10Soejima H, Ogawa H, Morimoto T, et al. Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level:subanalysis from the JPAD trial[J]. J Cardiol, 2013, 62:165-170.
